Home / Health / New Therapy Eradicates Childhood Brain Cancer in Mice
New Therapy Eradicates Childhood Brain Cancer in Mice
11 Nov
Summary
- Experimental therapy eliminated aggressive brain cancer in all tested mice.
- New approach uses engineered immune cells that activate only in the brain.
- Clinical trials for human testing are planned to begin by April 2027.
An experimental therapy has shown remarkable success, eradicating aggressive childhood brain cancer in all mice tested. This groundbreaking B-SYNC CAR-T therapy from UC San Francisco utilizes engineered immune cells designed to activate exclusively within the brain. This targeted approach aims to treat diffuse midline glioma (DMG), a devastating cancer with very limited treatment options.
The therapy involves genetically modifying a patient's T cells, equipping them with a biological switch that responds to specific brain signals. Once activated in the brain, these cells hunt tumor cells expressing certain proteins. In preclinical models, this method completely eliminated DMG tumors and demonstrated persistent protection against reintroduction of cancer cells.
This innovative technique offers significant hope for a disease with a high mortality rate. Researchers are now focused on advancing the therapy towards human testing, with a potential clinical trial at UCSF Health commencing as early as April 2027. Experts caution that while results are highly encouraging, human trials are crucial to establish safety and effectiveness.
